6XP Stock Overview
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr5.00 |
| 52 Week High | kr5.48 |
| 52 Week Low | kr4.84 |
| Beta | 0.97 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -1.4% |
| 1Y | n/a | -21.6% | 2.2% |
Return vs Industry: Insufficient data to determine how 6XP performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6XP performed against the German Market.
Price Volatility
| 6XP volatility | |
|---|---|
| 6XP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6XP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6XP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 26 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
Xspray Pharma AB (publ) Fundamentals Summary
| 6XP fundamental statistics | |
|---|---|
| Market cap | €127.01m |
| Earnings (TTM) | -€11.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.3x
P/E RatioIs 6XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XP income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr128.39m |
| Earnings | -kr128.39m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 17, 2023
| Earnings per share (EPS) | -5.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6XP perform over the long term?
See historical performance and comparison